The results elucidated that serum CEA of patients with lung adenocarcinoma was augmented versus patients with LSCC and SCLC, and serum SCC and CYFRA21-1 in patients with LSCC were elevated versus patients with lung adenocarcinoma and SCLC. This evidence concerns the gene CEACAM5 and lung adenocarcinoma.